Needham & Company Starts Akcea Therapeutics, Inc. (AKCA) at Buy

Needham & Company analyst Chad Messer initiates coverage on Akcea Therapeutics, Inc. (NASDAQ: AKCA) with a Buy rating and a price target of $45.00.

Messer commented, "Akcea Therapeutics is a majority owned subsidiary of Ionis Pharmaceuticals. Akcea was founded in 2014 as a wholly owned subsidiary to develop and commercialize three of Ionis’ rare lipid disease programs. However, the company has since broadened its activities and shareholder base. We believe AKCA is an attractive way for investors to leverage the decades of innovation at Ionis by owning a direct interest in several of its most advanced-stage programs."

For an analyst ratings summary and ratings history on Akcea Therapeutics, Inc. click here. For more ratings news on Akcea Therapeutics, Inc. click here.

Shares of Akcea Therapeutics, Inc. closed at $24.85 yesterday.

You May Also Be Interested In

• Needham Reiterates Buy Rating on Amazon.com (AMZN), Raises Estimates
• Piper Sandler Downgrades Southwestern Energy (SWN) to Neutral
• TD Cowen Resumes EQT Corp. (EQT) at Hold